357 reports of this reaction
3.3% of all EPIRUBICIN HYDROCHLORIDE reports
#6 most reported adverse reaction
FEBRILE NEUTROPENIA is the #6 most commonly reported adverse reaction for EPIRUBICIN HYDROCHLORIDE, manufactured by Pharmacia & Upjohn Company LLC. There are 357 FDA adverse event reports linking EPIRUBICIN HYDROCHLORIDE to FEBRILE NEUTROPENIA. This represents approximately 3.3% of all 10,973 adverse event reports for this drug.
Patients taking EPIRUBICIN HYDROCHLORIDE who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is moderately reported among EPIRUBICIN HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to febrile neutropenia, the following adverse reactions have been reported for EPIRUBICIN HYDROCHLORIDE:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 357 FDA reports for EPIRUBICIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 3.3% of all adverse event reports for EPIRUBICIN HYDROCHLORIDE, making it a notable side effect.
If you experience febrile neutropenia while taking EPIRUBICIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.